Objective-ADAMTS13 (a disintegrin and metalloprotease with thrombospondin type 1 repeats-13) cleaves VWF (von Willebrand factor). This process is essential for hemostasis. Severe deficiency of plasma ADAMTS13 activity, most commonly resulting from autoantibodies against ADAMTS13, causes thrombotic thrombocytopenic purpura. Therapeutic plasma exchange is the standard of care to date, which removes autoantibodies and replenishes ADAMTS13. However, such a therapy is often ineffective to raise plasma ADAMTS13 activity, and in-hospital mortality rate remains as high as 20%. Approach and Results-To overcome the inhibition by autoantibodies, we developed a novel approach by delivering rADAMTS13 (recombinant ADAMTS13 ) using platelets as vehicles. We show that both human and murine platelets can uptake rADAMTS13 ex vivo. The endocytosed rADAMTS13 within platelets remains intact, active, and is stored in α-granules. Under arterial shear (100 dyne/cm 2 ), the rADAMTS13 in platelets is released and effectively inhibits platelet adhesion and aggregation on a collagen-coated surface in a concentration-dependent manner. Transfusion of rADAMTS13-loaded platelets into Adamts13 −/− mice dramatically reduces the rate of thrombus formation in the mesenteric arterioles after FeCl 3 injury. An ex vivo transfusion of rADAMTS13-loaded platelets to a reconstituted whole blood containing plasma from a patient with immune-mediated thrombotic thrombocytopenic purpura and the cellular components (eg, erythrocytes and leukocytes) from a healthy individual, as well as a fresh whole blood obtained from a patient with congenital or immunemediated thrombotic thrombocytopenic purpura also dramatically reduces the rate of thrombus formation under arterial flow.
T hrombotic thrombocytopenic purpura (TTP) is a rare but potentially life-threatening clotting disorder. 1 It is characterized by severe thrombocytopenia and microangiopathic hemolytic anemia with varying degrees of damage to the brain, heart, pancreas, kidneys, and adrenal glands, etc. 2, 3 There are 2 main types of TTP: hereditary or congenital TTP (cTTP) and acquired or immune-mediated TTP (iTTP). cTTP is caused by mutations in ADAMTS13 gene, 4, 5 whereas iTTP is primarily caused by acquired autoantibodies targeting plasma ADAMTS13 (a disintegrin and metalloprotease with thrombospondin type 1 repeats-13) protein. 6, 7 The mechanisms of cTTP 1, 4 and iTTP 8, 9 have been extensively studied in the past decade.
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In most cases of cTTP, mutations in ADAMTS13 result in secretion defect of ADAMTS13 protein, 10 thus little to no ADAMTS13 protein and proteolytic activity can be detected in patients' plasma. However, in iTTP, an IgG type autoantibody binds ADAMTS13 protein, 8, 11 particularly to the spacer domain, a region critical for recognition and proteolysis of VWF (von Willebrand factor). 12, 13 Modifications to the ADAMTS13 spacer domain are shown to weaken or eliminate the autoantibody-binding sites while preserving ADAMTS13 activity.
14 Such antibody-resistant ADAMTS13 variants might be useful for therapy of iTTP. However, only 80% to 85% of patients may be benefited from such a strategy because 15% to 20% patients harbor autoantibodies that still recognize the antibody-resistant ADAMTS13 variants. 14 Other autoantibody-bypassing strategies, such as anti-VWF aptamer, 15, 16 anti-VWF nanobody caplacizumab, [17] [18] [19] and anti-GP-(glycoprotein) 1b anfibatide, [20] [21] [22] and N-acetylcysteine, 23, 24 have been tested for treatments for TTP with some success. However, none of these strategies would have addressed the underlying mechanism of lacking ADAMTS13.
In our previous study, we developed a transgenic mouse line in which a human rADAMTS13 (recombinant ADAMTS13) was expressed exclusively in platelets in the Adamts13 −/− background. 25 Platelet-expressed rADAMTS13 was efficacious in blocking arterial thrombosis and preventing a murine model of TTP induced by shigatoxin-2 and recombinant VWF. 25 To translate these proof-of-concept findings into patient care, we sought to determine whether platelets could be loaded with rADAMTS13 ex vivo after collection and whether transfusion of rADAMTS13-loaded platelets would be as efficacious as the transgenic platelets expressing high levels of rADAMTS13 for inhibiting arterial thrombosis under flow in human whole blood under flow and in vivo in a mouse model.
Here, we show that human platelets are able to endocytose rADAMTS13 in a time-, concentration-, and temperaturedependent manner; the endocytosed rADAMTS13 in platelets remains intact, proteolytically active, and releasable under arterial shear. Addition of rADAMTS13-loaded platelets to normal, TTP patient, or reconstituted TTP blood inhibits thrombus formation under arterial flow. Finally, transfusion of rADAMTS13-loaded murine platelets into Adamts13 −/− mice also dramatically inhibits thrombus formation in the mesenteric arterioles after oxidative injury. Our findings demonstrate that transfusion of rADAMTS13-loaded platelets may be developed as a novel therapeutic strategy for arterial thrombosis, primarily associated with cTTP and iTTP.
Materials and Methods
The data that support the findings of this study are available from the corresponding author upon reasonable request
Isolation of Human Platelets for Uptake of rADAMTS13
The IACUC (Institutional Review Board and the Institutional Animal Care and Use Committee) of the University of Alabama at Birmingham have approved the studies involving human and animal, respectively. Venous blood was collected from healthy donors, cTTP, and iTTP patients for the study after informed consent. Criteria for diagnosing cTTP and iTTP include severe thrombocytopenia, microangiopathic hemolytic anemia, and various signs and symptoms of organ damage as previously described. 26, 27 No evidence of cancer, hematopoietic progenitor transplantation, sepsis, and disseminated intravascular coagulation is present. All patients had their nitial plasma ADAMTS13 activity <10 U/dL without (cTTP) or with (iTTP) inhibitors or anti-ADAMTS13 IgG.
Ten milliliter whole blood was collected from each individual and anticoagulated with 10 µmol/L of thrombin inhibitor PPACK (D-phenylalanyl-L-prolyl-L-arginine chloromethyl ketone; SigmaAldrich). The anticoagulated blood was then centrifuged at 150g for 15 minutes to separate large blood cells (erythrocytes and leukocytes) from small cells (platelets). A Tyrode buffer (10 mmol/L HEPES, pH 7.4 containing 134 mmol/L NaCl, 2.7 mmol/L KCl, 1.0 mmol/L MgCl 2 , 12 mmol/L NaHCO 3 , and 0.34 mmol/L Na 2 HPO 4 ) was added to platelet-rich plasma and centrifuged for additional 10 minutes at 900g. The platelet pellet was resuspended in the Tyrode buffer before addition of rADAMTS13 at various concentrations. The rAD-AMTS13 was expressed using HEK (human embryonic kidney cell) 293 cells and was purified to homogeneity as previously described.
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Isolation of Murine Platelets for Uptake of rADAMTS13
Similarly, mouse blood (0.7-1.0 mL) was obtained through cardiac puncture after anesthesia with ketamine/xylazine cocktail and anticoagulated with 100 µmol/L of PPACK. One micromolar of prostaglandin E1 (Sigma-Aldrich) and 0.1 U/mL of apyrase (Sigma-Aldrich) were added to prevent platelet activation. The anticoagulated blood was then centrifuged at 100g for 10 minutes to obtain platelet-rich plasma, then centrifuged again at 400g for 10 minutes to obtain platelet pellets. The platelet pellets were resuspended in Tyrode buffer containing glucose (0.1%, wt/vol), BSA (0.35%, wt/vol), and magnesium (1 mmol/L). The platelets were incubated with human rADAMTS13 at various concentrations at 25°C for 120 minutes.
After incubation of rADAMTS13, both human and mouse platelets were washed twice with 1 mL of Tyrode buffer. Platelets were then used for the microfluidic assays or lysed with 20 mmol/L HEPES and 150 mmol/L NaCl, pH 7.4, containing 1% Triton X-100 to quantify levels of rADAMTS13 protein and activity in platelets using a fully automated Western blotting system (ProteinSimple) and in-house fluorescent resonance energy transfer-rVWF73 (recombinant 73-amino acid peptide derived from the central A2 domain of VWF) assay, 30, 31 respectively.
Western Blotting Using the Western Blotting System
Platelet lysates, prepared as stated in the section above, were used immediately for Western blotting using the automated Western blotting system. This size-based capillary electrophoresis system allowed for clean and quantitative results of protein signals. Two antibodies, a polyclonal antibody against human ADAMTS13, raised against human (80%) and murine (20%) recombinant ADAMTS13 (F481) 32 and a secondary antirabbit IgG peroxidase-conjugated (ProteinSimple) were used.
Assay for Platelet ADAMTS13 Activity
The proteolytic activity of rADAMTS13 in platelet lysate was determined by fluorescent resonance energy transfer-rVWF73 assay as described previously. 30, 31 Normal human plasma (CryoCheck) was used for calibration, defined as having 1 U/mL of ADAMTS13 activity.
Immunofluorescent Staining and Confocal Microscopy
Platelets were spread on a fibrinogen-coated surface and then fixed with ice-cold 4% paraformaldehyde in PBS for 10 minutes. The platelets were permeabilized with 0.1% Triton X-100 and incubated with a mouse anti-ADAMTS13 IgG (clone360, 1:50; Green Mountain Antibodies) conjugated with Alexa488, a rabbit anti-VWF IgG (1:100) conjugated with Alexa594 (Life Technologies 
Platelet Adhesion and Aggregation on a Collagen Surface Under Flow
BioFlux microfluidic channels (Fluxion Bioscience) were coated with a fibrillar collagen (100 µg/mL; Chrono-Log) in 0.01 N of hydrochloric acid underflow (shear rate of 500 s -1 ) for 10 minutes. The surface was blocked with 0.5% BSA in PBS. The platelets were labeled with fluorescein isothiocyanate-conjugated antihuman (1:10) or anti-murine (1:100) CD41 antibody for 15 minutes, then added into whole blood samples from a healthy donor, TTP patients, and Adamts13 −/− mice. The native or reconstituted whole blood samples were then perfused (100 dyne/cm 2 ) over the collagen-coated surfaces for 3 minutes. The time-lapse digital images were collected every 3 seconds for a total of 3 minutes. The relative fluorescent intensity or platelet coverage was determined off-line using Montage software and data were analyzed using GraphPad Prism7 software. 33 For high-resolution imaging, unbound platelets, leukocytes, and red blood cells were washed off from the channels with PBS for 10 minutes. The platelets adhered to the collagen surface were then fixed with ice-cold paraformaldehyde (4%) in PBS for 10 minutes. After being extensively washed and blocked with 2% BSA in PBS, the platelets were incubated with a fluorescein isothiocyanate-conjugated monoclonal anti-CD41 or GP-IIb IgG (Thermo Fisher Scientific) and an Alexa594-conjugated rabbit anti-VWF IgG (in-house conjugated with reagents from Thermo Fisher Scientific). Images were obtained with Nikon A1 confocal fluorescence microscope (Nikon).
Intravital Microscopic Imaging of Mesenteric Arterial Thrombosis in Mice
Mice (≈4 weeks) were anesthetized with intraperitoneal injection of ketamine/xylazine cocktail. Hundred microliter of rhodamine-6G (200 µg/mL) in PBS was infused via retro-orbital sinus plexus. Mesenteric vessels were exposed to 10% (wt/vol) FeCl 3 for 3 minutes. A Nikon fluorescent microscope equipped with a high-resolution digital camera determined the accumulation of fluorescent platelets and leukocytes in injured vessels. The time lapse was set for a total of 30 minutes, with acquisition of an image every 10 seconds. The relative fluorescent intensity was determined off-line, using the NIS-Elements software (Melville).
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Statistical Analysis
Mann-Whitney test was used for unpaired nonparametric data when 2 groups were compared. Kruskal-Wallis test was used for comparing data of ≥3 groups with nonparametric data. All graphs and statistical analysis were performed using Prism 7 software (GraphPad). 
Results
Human and Mouse Platelets Uptake rADAMTS13 Ex Vivo in a Time-, Temperature-, and Concentration-Dependent Manner
Normal human platelets are known to contain trace amounts of ADAMTS13, which may be synthesized in megakaryocytes or endocytosed from plasma. 34 To determine whether platelets were able to uptake rADAMTS13 ex vivo, human platelets were isolated, washed, and incubated with varying concentrations of rADAMTS13 (0, 5, 20, 40, and 80 μg/mL) at 3 different temperatures (4°C, 25°C, and 37°C) for 0 to 120 minutes. After unbound rADAMTS13 was removed by gentle washing, remaining platelets (<50% of initial number of platelets) were either lysed or fixed for Western blotting or proteolytic activity or fluorescent confocal microscopy. Figure 1 showed that at low temperature (4°C) there was no rADATMS13 detected inside or on human platelets even after 2 hours of incubation at the highest concentration of 80 μg/mL; at 25°C and 37°C, a concentration-dependent increase of rADAMTS13 protein signal and activity in platelet lysates was detected. Interestingly, there was no statistically significant difference in the amount of rADAMTS13 protein in platelets after being incubated with rADAMTS13 at 25°C compared with incubation at 37°C. Surprisingly, even at much lower concentrations (5-10 μg/mL), platelets could endocytose detectable amount of rADAMTS13 ( Figure I in the online-only Data Supplement). Together, these results suggest that rADAMTS13 can be sufficiently loaded into platelets ex vivo at temperatures where platelets are normally stored before transfusion.
Localization of rADAMTS13 in Human Platelets
To assess where rADAMTS13 endocytosed was stored in platelets, we performed immunofluorescent analysis after fixation. A positive signal of rADAMTS13 was only detected in human platelets that were incubated with rAD-AMTS13 (5-20 μg/mL) for 2 hours (Figure 2A and 2G ), but not in those incubated with buffer alone ( Figure 2B ). As expected, all platelets were stained positive for VWF ( Figure 2C , 2D, and 2H), which served as an internal control. The merged images of multiple platelets at the low magnification (×20; Figure 2E and 2F) or a single platelet at the Figure 2 . Immunofluorescent microscopy demonstrates the colocalization of rADAMTS13 (recombinant a disintegrin and metalloprotease with thrombospondin type 1 repeats-13) with VWF (von Willebrand factor) in human platelets. Isolated and washed human platelets were incubated with rADAMTS13 (20 μg/mL) at 37°C for 2 h and fixed with 4% paraformaldehyde in PBS for 10 min. Alexa594-conjugated (red) monoclonal anti-ADAMTS13 IgG (A, B, and G) and Alexa488-conjugated (green) rabbit anti-VWF IgG (C, D, and H) were used to determine the presence of rADAMTS13 and VWF, respectively. Combined images, including rADAMTS13, VWF, and F-actin (stained with Alexa350-conjugated actin-binding protein phalloidin) are shown in E, F, and I. The images in A-F were obtained by confocal microscope under a magnification of ×20, whereas 3-dimensional images in panels G-I were obtained using the same confocal microscope under a magnification of ×100. The bars represent 2 μm in length. αG indicates platelet α-granules; and A13 or rA13, recombinant ADAMTS13.
high magnification (×100; Figure 2G , 2H, and 2I) revealed punctuated staining patterns of both rADAMTS13 and VWF. The blue staining is F-actin. These results indicate that rAD-AMTS13 and VWF are at least partially colocalized to the platelet α-granules.
rADAMTS13 in Platelets is Releasable, Which Inhibits Platelet/VWF Aggregates in Normal Whole Blood Under Flow
To determine whether the rADAMTS13 endocytosed in platelets is able to be released and cleave VWF/platelet aggregates underflow, a microfluidic assay was performed. Platelets were incubated with an increasing concentration of rADAMTS13 (0, 5, and 10 μg/mL). A reconstituted whole blood sample was created by mixing the rADAMTS13-loaded platelets after washing with a Tyrode buffer and washed red/white blood cells from healthy individuals. Because of the removal of plasma ADAMTS13 and VWF during the washing step, purified VWF (10 μg/mL) was added to restore normal VWF function in the reconstituted whole blood. Platelets incubated with a Tyrode buffer alone were used as a control. The reconstituted whole blood, including control platelets and rADAMTS13-loaded platelets, was then flowed under shear (100 dyne/cm 2 ) through the microfluidic channels coated with fibrillar collagen.
As shown, the rate of accumulation ( Figure 3A and 3B) and the final surface coverage ( Figure 3C and 3D ) of fluorescent platelets on the collagen-coated surface were dramatically reduced in the channel where rADAMTS13-loaded platelets were included compared with the control (with same number of platelets containing no rADAMTS13). Such an antithrombotic effect of rADAMTS13-loaded platelets was dependent on the concentration rADAMTS13 used during platelet uptake: the more rADAMTS13 was used for uptake, the better antithrombotic efficacy of these platelets was (Figure 3) . These results indicate that rADAMTS13 endocytosed by platelets is functional and able to be released to cleave VWF and VWF-platelet aggregates under arterial shear.
rADAMTS13 in Platelets is Efficacious in Inhibiting Thrombus Formation Under Flow in TTP Patients' Blood
To assess whether transfusion of rADAMTS13-loaded platelets would be efficacious in treating TTP, we preloaded platelets with rADAMTS13 (0, 5, and 10 μg/mL) on the day of admission of a TTP patient as described in the Materials and Figure 3 . The rADAMTS13 (recombinant a disintegrin and metalloprotease with thrombospondin type 1 repeats-13)-loaded platelets (Plts) exhibit an antithrombotic activity underflow in a whole blood from a healthy donor. Isolated and washed Plts were incubated with rADAMTS13 at 0, 5, and 10 μg/mL at 37°C for 2 h. The residual rADAMTS13 was removed by centrifugation and 3 washes. The rADAMTS13-loaded Plts were then added back to the washed cellular components, including red blood cells and white blood cells with supplementation of VWF (von Willebrand factor; 10 μg/mL). The washes removed all plasma ADAMTS13. The reconstituted whole blood with 150×10
Method. Whole blood was collected from a patient with cTTP or iTTP (Table I in the online-only Data Supplement) before the initiation of plasma therapy and anticoagulated with the thrombin inhibitor PPACK (10 μg/mL). As shown, when added to the whole blood from a patient with cTTP ( Figure 4A-4D ) or 2 iTTP patients ( Figure 4E-4H) , washed rADAMTS13-loaded platelets (5 and 10 μg/mL) exhibited antithrombotic effect under arterial flow. In both cases, the rate of accumulation ( Figure 4A and 4B ) and the final coverage ( Figure 4C and 4D) of fluorescently-labeled platelets on the collagen-coated surface was significantly inhibited compared with those with the control platelets.
Also, the elongated VWF/platelet strings and large aggregates were detected on the collagen-coated surface in the controls, but not in those supplemented with rADAMTS13-loaded platelets (estimated ≈0.05 ng of rADAMTS13/10 6 platelets; Figure 4C , 4D, 4G, and 4H). However, there was no significant dose-dependency on the rADAMTS13 used for platelet preparation ( Figure 4A and 4B), suggesting that only a small amount of rADAMTS13 within platelets is required for such an antithrombotic activity underflow. Together, our results demonstrate that rADAMTS13-loaded platelets are efficacious for inhibiting arterial thrombosis under flow in patients with either cTTP or iTTP.
rADAMTS13 in Platelets is Efficacious in Inhibiting Thrombus Formation Under Flow in a Reconstituted Whole Blood Containing Various Titers of Autoantibodies
To demonstrate the variability and efficacies of rADAMTS13-loaded platelets for inhibiting thrombus formation in iTTP patients, we took advantage of the Alabama TTP Patient Cohort, a large collection of iTTP patient plasma samples with various titers of inhibitors (Table I in the online-only Data Supplement). Normal human platelets preloaded with rADAMTS13 (0, 5, and 10 μg/mL) were added to a reconstituted whole blood containing plasma from an iTTP patient and washed cellular components (primarily erythrocytes and leukocytes) from a healthy donor in the presence of 10 μg/ mL of purified VWF. The control contained normal human platelets that were not loaded with rADAMTS13. The whole blood samples were then flown over the fibrillar collagencoated surface under arterial shear (100 dyne/cm 2 ). The rates of accumulation and the final surface coverage of fluorescently-labeled platelets were determined using the microfluidic system. As shown, the addition of rADAMTS13-loaded platelets (5 and 10 μg/mL) dramatically reduced the rates and final surface coverage when compared with the controls (Figure 5A-5D ). Each experiment was repeated 4× using 4 different patient plasma samples and 4 different healthy donor blood cells for reconstitution; the means and SEs of the means were determined (Figure 5A and 5C ). These results suggest that the antithrombotic effect of rADAMTS13-loaded platelets under arterial shear is highly reproducible.
Immunohistochemistry and confocal analyses demonstrated the reduction of platelet adhesion and aggregation ( Figure 5E ) corresponded to the reduction of VWF accumulation ( Figure 5F ) in the channels containing rAD-AMTS13-loaded platelets when compared with those in the controls. Z-stack confocal image analysis revealed that the mean thicknesses of platelet aggregates ( Figure 5H ) and VWF accumulation ( Figure 5I ) in the channel treated with control platelets (≈45 μm) were significantly greater than those in the channel treated with rADAMTS13-platelets (≈24 μm). One could better appreciate more for the differences between the control and the experimental group in the merged confocal images of platelet/VWF staining ( Figure 5G and 5J) . These results further support the hypothesis that rADAMTS13-loaded platelets are able to release rADAMTS13 at the site of injury, which inhibits the thrombus growth underflow despite the presence of circulating antibodies against ADAMTS13.
rADAMTS13 in Murine Platelets Inhibits Thrombosis in a Mesenteric Arteriole of
Adamts13 −/− Mice After FeCl 3 Injury
To determine if platelets loaded with rADAMTS13 was able to inhibit arterial thrombosis in vivo, murine platelets were isolated from Adamts13 −/− mice and incubated at 37°C for 1 hour with rADAMTS13 (0, 5, and 10 μg/mL) in Tyrode buffer. We also isolated platelets from transgenic mice expressing rADAMTS13 exclusively in platelets as a positive control and platelets from Adamts13 −/− mice as a negative control. We then transfused platelets that lack ADAMTS13, platelets preloaded with rADAMTS13 (5 μg/mL), or transgenic platelets containing rADAMTS13 into Adamts13 −/− mice via the retro-orbital plexus. Injury was induced using 10% FeCl 3 to Figure 4 Continued. immune-mediated TTP (iTTP; E-H). The reconstituted whole blood was flowed over a fibrillar collagen-coated surface under arterial shear (100 dyne/cm 2 ) for 3 min. The rate of accumulation (A and B, E and F) and the final surface coverage (C and D, G and H) of fluorescently-labeled Plts were determined under an inverted microscope. The rates of platelet accumulation as a function of time in A, B, E, and F were plotted using Prism 7 software. AU indicates arbitrary unit; and rA13, recombinant ADAMTS13. the mesenteric arterioles 2 minutes after platelet transfusion, and real-time images were obtained under an inverted fluorescent microscope.
As shown, transfusion of platelets preloaded with rAD-AMTS13 or transgenic platelets containing rADAMTS13 at the concentration of 10% of total platelets (≈60×10 3 /μL, final), resulted in a dramatic reduction in the rates of platelet adhesion and aggregation (ie, thrombus formation) at the site of injury (Figure 6A-6C) . As a control, transfusion of platelets that lack ADAMTS13, which contained no rADAMTS13, had no effect ( Figure 6B and 6C) . Within 12 minutes, the rate of thrombus formation in this group reached a plateau ( Figure 6B and 6C) , similar to what we observed in Adamts13 −/− mice without being transfused (not shown). The rate of thrombus formation in the mesenteric arterioles of mice that received platelets preloaded with rADAMTS13 or transgenic platelets containing rADAMTS13 was parallel to that observed in wild-type mice that contained plasma ADAMTS13 (≈1 μg/mL; Figure 6B and 6C). The estimated concentrations of platelet-delivered rAD-AMTS13 in murine whole blood and plasma were ≈50 and ≈100 ng/mL, respectively, which is at least 20-folds less than the concentrations of soluble ADAMTS13 plasma of normal mice. However, a direct comparison of the antithrombotic efficacy between platelet-delivered rADAMTS13 and soluble rADAMTS13 in cTTP and iTTP patients' blood should be performed in our future studies. Nevertheless, these results demonstrate that transfusion of rADAMTS13-loaded platelets may be efficacious for inhibiting arterial thrombosis under (patho) physiological conditions.
Discussion
In the present study, we demonstrate that human and murine platelets are able to endocytose rADAMTS13 in vitro at room temperature. This uptaking condition is compatible with that used for storing platelet products before transfusion in the blood bank. The endocytosed rADAMTS13 protease within platelets remains intact, proteolytically active, and is stored in α-granules. The rADAMTS13-loaded platelets show an antithrombotic activity ex vivo under arterial shear and in vivo in the absence or presence of autoantibodies against ADAMTS13. These findings support a working hypothesis that transfusion of rADAMTS13-loaded platelets may be therapeutically efficacious for inhibiting arterial thrombosis, such as in patients with TTP and other types of pathological Figure 5 . The rADAMTS13 (recombinant a disintegrin and metalloprotease with thrombospondin type 1 repeats-13)-loaded platelets (Plts) inhibit arterial thrombosis under flow in reconstituted whole blood consisting of immune-mediated thrombotic thrombocytopenic purpura (iTTP) patient plasma and normal red blood cells (RBC) and white blood cells (WBC). rADAMTS13-loaded Plts (5 and 10 μg/mL) were added to a reconstituted whole blood consisting of iTTP patient plasma with various titers of inhibitor and washed cellular components (RBC and WBC) from a healthy donor with an addition of purified VWF (von Willebrand factor; 10 μg/mL). The reconstituted whole blood samples with 150×10 3 /μL of Plts (control Plts vs rADAMTS13-loaded Plts) were perfused over a fibrillar collagen-coated surface under arterial shear (100 dyne/cm 2 ) for 3 min. The rates of accumulation (A and B) and the final coverage (C and D) of fluorescently-labeled Plts on the collagen-coated surfaces were determined using the microfluidic system. The data shown are the means±SEM of 4 independent experiments. Immunofluorescent staining with fluorescein isothiocyanate-conjugated monoclonal anti-CD41 (Continued ) thrombosis associated with an absolute or relative deficiency of ADAMTS13 activity.
Platelets are the first cells to arrive at the site of injury and are known to participate in many physiological and pathophysiological processes, including inflammation, wound healing, atherosclerosis, antimicrobial host defense, angiogenesis, and protection against malignancy in addition to hemostasis and thrombosis. 35 Each platelet contains 50 to 80 α-granules filled with a variety of proteins, including those synthesized in megakaryocytes (eg, VWF, P-selectin, integrin αIIbβ3, and growth factors) and those endocytosed through cell surface receptors from plasma environments (eg, fibrinogen, fibronectin, and factor V). 35, 36 Therefore, platelets are considered to be an excellent vehicle to store and deliver a therapeutic agent (or protein) for treatments of various disorders, including bleeding diathesis, thrombotic disorders, and malignancy.
Previous studies have evaluated the therapeutic efficacy of platelet-delivered hemostatic agents by transgenic expression of such proteins under a platelet-specific promoter in megakaryocytes, which directs the storage of a therapeutic protein to the α-granules. [37] [38] [39] For instance, ectopic expression of FVIII (factor VIII) or FIX (factor IX) in platelets results in improvement of clinical phenotype of murine model of hemophilia A 40, 41 or hemophilia B 42 . Transplantation of hematopoietic progenitor cells transduced with a lentiviral vector carrying a therapeutic gene, such as FVIII or FIX under platelet-specific promoter was also effective. Platelet-delivered FVIII is more effective than an equal amount of infused FVIII in the presence of inhibitors. 40, 41 However, such a similar protective role for platelet-delivered FIX was only observed without an inhibitor, but not in mice with anti-FIX inhibitors. 42 In our study, we demonstrate a dramatic antithrombotic effect of platelet-delivered rADAMTS13 ex vivo using a microfluidic system, which mimics the formation of sheardependent and platelet/VWF-rich thrombi inside small arterioles; additionally, we show that platelet-delivered rAD-AMTS13 inhibits thrombus formation in Adamts13 −/− mice. Such an effect is sustained in a whole blood reconstituted and from a real TTP patient with or without anti-ADAMTS13 inhibitors. While only small amount of rADAMTS13 protease may be released from preloaded platelets, this amount appears to affect the formation of ultra-long VWF strings or to inhibit the formation of large and thick VWF-platelet aggregates on the collagen-coated surface underflow. These results are consistent with those we have previously reported in transgenic mice, in which the ectopically expressed Figure 6 . The rADAMTS13 (recombinant a disintegrin and metalloprotease with thrombospondin type 1 repeats-13)-loaded murine platelets (Plts) inhibit the rate of thrombus formation in mesenteric arterioles of Adamts13 −/− mice after FeCl 3 injury. A, Schematic representation of mesenteric arteriole network and the position where a piece of filter paper with 10% FeCl 3 (wt/vol) was placed. B, The means and SEs of the means (SEM) of the rates of thrombus formation as a function of time in each group were quantified off-line using the NIS-Elements software and plotted using the Prism 7 software. C, Time lapses demonstrate the rates of thrombus formation induced by 10% FeCl 3 injury to the mesenteric arterioles in Adamts13 −/− mice after being transfused with 10% of rADAMTS13-loaded Plts (rA13-Plts), transgenic plts expressing rADAMTS13 (TG-Plts), and Plts from Adamts13 −/− mice (KO-Plts) or in wild-type mice (WT). All Plts (both infused and endogenous) were labeled with a rhodamine-6G. Representative digital images at 0, 5, 10, and 20 min in 4 different experimental groups are shown. rA13 indicates recombinant ADAMTS13. rADAMTS13 in platelets is highly efficacious for inhibiting the rate of thrombus formation in the mesenteric arterioles of mice after FeCl 3 injury, and protecting mice from developing a TTP-like syndrome after shiga toxin-2 or recombinant VWF challenge. 25 Our current study has not only confirmed and extended our previous proof-of-concept findings in transgenic mice, but also demonstrated that transfusion of a small number of rADAMTS13-loaded platelets (≈10% of total number of platelets) into a recipient that lacks circulating ADAMTS13, such as in Adamts13 −/− mice or in patients with cTTP or iTTP, maybe also efficacious for inhibiting microvascular thrombosis. Such an antithrombotic effect is reproducible under the conditions used and even observed after the rADATMS13-loaded platelets are stored at 4°C for >24 hours (data not shown).
Our findings offer the possibility of translating this novel approach into patient care once rADAMTS13 receives the approval from Food and Drug Administration of the United States of America for therapy of cTTP. 43 A clinical trial will be designed to test the efficacy of transfusion of rADAMTS13-loaded platelets for the treatment of both cTTP and iTTP. This can be accomplished by adding rADAMTS13 into the single donor platelets at the concentration of 5 to 10 μg/mL using an aseptic technique. After several hours of incubation, the rADAMTS13-loaded platelets will be ready for transfusion into patients.
In addition to the data presented, we are able to show that detectable amounts of rADAMTS13 can be endocytosed in the presence of normal plasma proteins in vivo in Adamts13 −/− mice ( Figure II in the online-only Data Supplement). We anticipate that platelet-delivered rADAMTS13 may be more efficacious than plasma rADAMTS13 for both cTTP and iTTP because rADAMTS13 can be delivered to the site of thrombus formation at a more concentrated fashion and is likely shielded from inhibition by anti-ADAMTS13 antibodies. Additionally, the half-life of rADAMTS13 inside platelets may be much longer than that in solution, which is typically 2 to 3 days in the absence of inhibitors 43, 44 but can be dramatically reduced due to the rapid clearance of immune complexes. 45, 46 This may avoid the need for daily plasma exchange as the standard of care for now for iTTP.
Platelet transfusions are currently avoided in patients with TTP because of a perceived risk for exacerbating thrombosis according to anecdotal reports. 47, 48 However, a large cohort study has demonstrated that TTP patients who have received platelet transfusion do not exhibit increased morbidity or mortality nor has it increased thrombotic events when compared with those who do not. 49, 50 Our in vitro experiments with reconstituted blood or real-time iTTP patient whole blood samples, as well as in vivo thrombus formation experiments have demonstrated the antithrombotic effects of rADAMTS13-loaded platelets when added or transfused into whole blood both ex vivo and in vivo.
A potential pitfall in our present study is that only prophylactic effect of rADAMTS13-loaded platelets was assessed. The efficacy of rADAMTS13-loaded platelets in the presence of established (large and small) thrombi is yet to be determined in our future studies. Nevertheless, we believe that transfusion of rADAMTS13-loaded platelets may be developed as a potential novel therapeutic for various arterial thromboses, particularly associated with congenital and immune-mediated TTP.
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